Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

404P - Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Immunotherapy

Tumour Site

Presenters

Jia-Hui Weng

Citation

Annals of Oncology (2020) 31 (suppl_6): S1386-S1406. 10.1016/annonc/annonc367

Authors

J. Weng1, W. Huang1, K. Xu2, P. Li2, L. Wang2, Y. Zhang2, J. Wang1, J. Liu1

Author affiliations

  • 1 Lung Cancer Center, West China School of Medicine/West China Hospital of Sichuan University, 610041 - Chengdu/CN
  • 2 /, West China School of Medicine/West China Hospital of Sichuan University, 610041 - Chengdu/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 404P

Background

Patients with advanced lung cancer are considered to have a poor prognosis, and recent studies have shown that immunotherapy appears to be associated with improved prognosis and prolonged survival significantly compared with chemotherapy. However, immunotherapy may refer to a comparatively high medical cost and bring severe financial toxicity to patients. In the treatment course of patients with advanced lung cancer, much attention was paid to the safety and efficacy of medications, rather than financial toxicity, which may affect the prognosis and survival indeed. In that case, it is necessary to weigh the profit and the financial toxicity led by immunotherapy.

Methods

We performed a systematic search in Medline on the cost-effectiveness of immunotherapy in patients with advanced lung cancer, and 16 studies were included, consisting of 6 countries, We systematically reviewed the incremental cost for improved quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) in patients treated with immunotherapy with respect to different countries and different tumor proportion score (TPS) of programmed death receptor-1 ligand (PD-L1).

Results

We found that the willingness to pay (WTP) was not significantly associated with ICER among three western countries (P=0.354). Patients with TPS ≥50%, ≥20%, or ≥1% showed no significant differences in elevated QALYs (P=0.148) and ICER (P=0.263). The elevated QALYs (P=0.024) and ICER of Pembrolizumab were significantly higher than that of Atezolizumab (P=0.045), while there was no significant difference in the cost of elevated QALY between Pembrolizumab and Atezolizumab (P=0.747).

Conclusions

Patients with advanced lung cancer would get profit in the treatment of immunotherapy from different countries, while Pembrolizumab would be associated with a higher benefit and less financial toxicity when taking cost-effectiveness analysis into account. Thus, patients would get more in the immunotherapy when financial toxicity was taken into consideration, and it is necessary to integrate financial toxicity in the clinical decision.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.